Compile Data Set for Download or QSAR
Report error Found 105 Enz. Inhib. hit(s) with all data for entry = 13121
Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760979(US20250241905, Compound 55)
Affinity DataIC50: 0.700nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760949(US20250241905, Compound 25)
Affinity DataIC50: 1nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760929(US20250241905, Compound 5)
Affinity DataIC50: 1.40nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760983(US20250241905, Compound 59)
Affinity DataIC50: 3.80nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760935(US20250241905, Compound 11)
Affinity DataIC50: 4.80nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760931(US20250241905, Compound 7)
Affinity DataIC50: 7.20nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760933(US20250241905, Compound 9)
Affinity DataIC50: 10nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760926(US20250241905, Compound 2)
Affinity DataIC50: 14nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760972(US20250241905, Compound 48)
Affinity DataIC50: 19nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM761015(US20250241905, Compound 91)
Affinity DataIC50: 25nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760973(US20250241905, Compound 49)
Affinity DataIC50: 26nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760933(US20250241905, Compound 9)
Affinity DataIC50: 37nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM761003(US20250241905, Compound 79)
Affinity DataIC50: 38nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760970(US20250241905, Compound 46)
Affinity DataIC50: 42nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760926(US20250241905, Compound 2)
Affinity DataIC50: 45nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM761011(US20250241905, Compound 87)
Affinity DataIC50: 45nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760947(US20250241905, Compound 23)
Affinity DataIC50: 49nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760930(US20250241905, Compound 6)
Affinity DataIC50: 51nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM761014(US20250241905, Compound 90)
Affinity DataIC50: 52nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760982(US20250241905, Compound 58)
Affinity DataIC50: 55nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760960(US20250241905, Compound 36)
Affinity DataIC50: 59nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760925(US20250241905, Compound 1)
Affinity DataIC50: 62nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760931(US20250241905, Compound 7)
Affinity DataIC50: 64nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760995(US20250241905, Compound 71)
Affinity DataIC50: 67nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM761016(US20250241905, Compound 92)
Affinity DataIC50: 68nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760965(US20250241905, Compound 41)
Affinity DataIC50: 68nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760935(US20250241905, Compound 11)
Affinity DataIC50: 68nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760983(US20250241905, Compound 59)
Affinity DataIC50: 71nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760929(US20250241905, Compound 5)
Affinity DataIC50: 71nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760981(US20250241905, Compound 57)
Affinity DataIC50: 78nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM761012(US20250241905, Compound 88)
Affinity DataIC50: 78nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760934(US20250241905, Compound 10)
Affinity DataIC50: 79nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760965(US20250241905, Compound 41)
Affinity DataIC50: 79nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760925(US20250241905, Compound 1)
Affinity DataIC50: 83nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760948(US20250241905, Compound 24)
Affinity DataIC50: 83nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760949(US20250241905, Compound 25)
Affinity DataIC50: 84nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760979(US20250241905, Compound 55)
Affinity DataIC50: 89nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760956(US20250241905, Compound 32)
Affinity DataIC50: 90nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760959(US20250241905, Compound 35)
Affinity DataIC50: 92nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM761019(US20250241905, Compound 95)
Affinity DataIC50: 100nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760932(US20250241905, Compound 8)
Affinity DataIC50: 105nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760978(US20250241905, Compound 54)
Affinity DataIC50: 107nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760980(US20250241905, Compound 56)
Affinity DataIC50: 110nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760997(US20250241905, Compound 73)
Affinity DataIC50: 122nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760985(US20250241905, Compound 61)
Affinity DataIC50: 127nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760953(US20250241905, Compound 29)
Affinity DataIC50: 130nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM761017(US20250241905, Compound 93)
Affinity DataIC50: 131nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760975(US20250241905, Compound 51)
Affinity DataIC50: 149nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM761004(US20250241905, Compound 80)
Affinity DataIC50: 152nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Target3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 [15-386,I190T](Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM760971(US20250241905, Compound 47)
Affinity DataIC50: 177nMAssay Description:DHEA and NAD+ were enzymatically converted to androstenedione and NADH, respectively. Final NADH concentrations were spectroscopically quantified usi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/12/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 105 total ) | Next | Last >>
Jump to: